Esketo Tablet contains Alpha Ketoanalogue (NA), a specialized nutritional supplement designed to support patients with chronic kidney disease (CKD) by providing essential amino acid precursors without contributing to nitrogenous waste accumulation. Alpha Ketoanalogue serves as a nitrogen-free analog of essential amino acids, which, upon transamination in the body, helps maintain protein synthesis while minimizing the production of uremic toxins. This mechanism is particularly beneficial in patients undergoing protein-restricted diets, as it aids in preserving nutritional status and delaying the progression of renal impairment. Esketo Tablet is indicated as an adjunct therapy in the management of CKD stages 3 to 5, especially in individuals on low-protein diets, to reduce the metabolic burden on compromised kidneys. The formulation supports nitrogen balance, reduces azotemia, and may improve overall patient outcomes by mitigating symptoms associated with renal insufficiency. Administration should be under medical supervision, with dosage adjusted according to renal function and dietary protein intake. Esketo Tablet is contraindicated in patients with hypersensitivity to any component and should be used cautiously in those with hepatic dysfunction. Regular monitoring of renal parameters and nutritional status is recommended during therapy to optimize treatment efficacy and safety.